Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SLN
SILENCE THERAPEUTICS PLC
NASDAQ
$13.42
▼ DOWN 0.22% (-0.03)

KEY STATISTICS

Market Cap$633.88 M
52w High$17.58
52w Low$4.19
Dividend Yield—
Frequency—
P/E-10.48
Volume539.70K
Shares Out.47.23M

COMPANY

LEADERSHIP

Iain Gladstone Ross
CHIEF EXECUTIVE
Iain Gladstone Ross

COMPENSATION 2026

Salary$690,687
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$27,913
Total$2,246,863

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 8, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
88

PRICE TARGET

Target High$67.00
Target Low$49.00
Target Median$55.00
Target Consensus$57.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$124.22K
NOV
5
THU

PRICE

$13.42 ▼ DOWN 0.22% (−$0.03)
$13.20$13.35$13.50$13.659:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.42

About Silence Therapeutics plc

https://www.silence-therapeutics.com ↗

Silence Therapeutics plc is a UK biotech developing RNA interference therapies for hematology, cardiovascular, and rare diseases, with clinical-stage candidates and collaborations with AstraZeneca, Mallinckrodt, and Hansoh.

INDUSTRY

Biotechnology

A PRODUCT SILENCE THERAPEUTICS PLC IS KNOWN FOR

Divesiran (SLN124)
Divesiran (SLN124)

Divesiran is an investigational siRNA therapy in Phase 2 for polycythemia vera, a rare blood cancer, representing a potential first-in-class treatment and a key advancement in Silence Therapeutics' pipeline.

COMPETITORS

COMPETITOR
ABUS COMPARE
ALNY COMPARE
ARWR COMPARE
IONS COMPARE
PTGX COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q4-2025
Research Collaboration Income$100K $224K ▲$235K ▲

Revenue by Geography

MapREGIONFY2021FY2022FY2023FY2024
GERMANY$392K $578K ▲$569K ▼$144K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
5
RANKED BY POSITION SIZE
IBB
0.02% · 195.1K
GWX
0.01% · 9.7K
APIE
0.01% · 8.1K
IBBQ
0.04% · 2.9K
BIB
0.02% · 1.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
41.64%
HOLDERS
71
TOP 12 OF 71 · RANKED BY POSITION SIZE
Tcg Crossover Management, LLC
3.0M sh · $15.99M
Siren, L.L.C.
2.9M sh · $15.34M
Redmile Group, LLC
2.2M sh · $11.41M
Nantahala Capital Management, LLC
2.1M sh · $11.31M
Lombard Odier Asset Management (Usa) Corp
1.8M sh · $7.12M
Citadel Advisors LLC
1.2M sh · $6.51M
Morgan Stanley
1.2M sh · $6.27M
Vivo Capital, LLC
1.1M sh · $5.74M
Millennium Management LLC
1.1M sh · $5.66M
Great Point Partners LLC
1.0M sh · $5.38M
Frazier Life Sciences Management, L.P.
970.1K sh · $5.03M
Nextech Invest, Ltd.
952.4K sh · $5.02M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
Griffiths Richard Ian
Sale · 382.0K shares
2026-08-10
★
10 PERCENT OWNER
Griffiths Richard Ian
Sale · 800.0K shares
2026-08-10
★
10 PERCENT OWNER
Griffiths Richard Ian
Sale · 100.0K shares
2026-08-10
★
10 PERCENT OWNER
Griffiths Richard Ian
Sale · 2.8M shares
2026-08-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS
Morgan Stanley OVERWEIGHT HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ANRO$35.13COMPARE
CTNM$17.05COMPARE
CAPR$9.59COMPARE
KYTX$8.37COMPARE
LXEO$4.86COMPARE
LYEL$14.53COMPARE
AMRN$13.97COMPARE
ACIU$2.65COMPARE